Diosmin and horse chestnut: the European venoactive standard

Most of what we write about supplement evidence is a story of overstated claims. This is one of the exceptions, and it is worth being precise about why.

Diosmin-hesperidin and horse chestnut seed extract have a better evidence base than almost anything else in the herbal category, good enough that in parts of Europe they are regulated as medicines rather than supplements, and good enough to appear in clinical guidance on chronic venous disease.

And they still do not do what the packs in India imply. That distinction is the article.

This is information, not medical advice. Sudden pain and swelling in one calf can be a deep vein thrombosis, a medical emergency. See a doctor.

What “venoactive” means

This is a recognised drug class in European practice, phlebotonics or venoactive drugs, and it has no real equivalent in the Indian regulatory landscape, which is why the same substances are supplements here.

What they are proposed to do:

• Increase venous tone, reducing the distensibility of the vein wall
• Reduce capillary permeability, which is the main proposed mechanism for the effect on swelling
• Improve lymphatic drainage
• Reduce leukocyte adhesion to the vein wall and the inflammation that follows, this is thought to be central to the skin changes of advanced venous disease
• And improve blood rheology, how it flows

And the honest framing of the whole class: they address symptoms and oedema. They do not repair incompetent valves, and no oral agent does.

Diosmin and hesperidin

What it is

Diosmin is a flavonoid, derived industrially from hesperidin, which comes from citrus peel, Citrus aurantium and related species.

The best-studied preparation is not plain diosmin. It is MPFF, micronised purified flavonoid fraction, typically 90% diosmin and 10% other flavonoids expressed as hesperidin, in a micronised form.

And the micronisation is not a marketing detail. Diosmin is poorly water-soluble, and reducing particle size substantially improves its absorption. The clinical trials were done with the micronised preparation. A non-micronised diosmin tablet at the same stated dose is not the same product, and this is the single most important technical point in this article.

The evidence

This is the strongest evidence in the venoactive class.

Systematic reviews of phlebotonics in chronic venous insufficiency report benefit for oedema, with moderate-quality evidence, and more variable effects on symptoms such as pain, heaviness, cramps and restless legs. The effects are modest in size and consistent in direction.

MPFF specifically has the largest trial base, including trials on symptom relief and oedema.

And it appears in clinical guidance on chronic venous disease as an option for symptom relief, generally alongside compression rather than instead of it, which is exactly how it should be positioned.

Venous leg ulcers: there is reasonable evidence that MPFF added to compression improves healing rates in venous ulcers. This is the most clinically meaningful finding in the whole class and it is specific to that adjunctive use.

Haemorrhoids: diosmin-hesperidin is also widely used for acute haemorrhoidal symptoms, with supportive trial evidence, a separate indication frequently conflated with the leg-vein one.

Post-procedure: used in some protocols after vein ablation or sclerotherapy.

Dose

The dose used in the trials is specific and it is the thing most Indian labels fall short of.

MPFF trials typically used 1000 mg daily (as 500 mg twice daily, or a single 1000 mg dose of the newer formulation), continued for weeks to months.

A product containing 100 mg of diosmin is not a lower dose of the same thing. It is below the studied range, and it cannot borrow the trial evidence. If you are comparing labels, this is where to look, and it is where most of this market fails.

Safety

Generally well tolerated. Mild gastrointestinal upset and headache are the common complaints.

Cautions:

Pregnancy and lactation, data are limited and it is generally avoided, particularly in the first trimester.

Anticoagulants and antiplatelets, theoretical additive effect; tell your doctor.

And a genuine one people miss: citrus flavonoids and the CYP3A4 pathway. Grapefruit’s interaction with many medicines runs through this enzyme, and high-dose citrus flavonoid supplements warrant caution alongside drugs metabolised that way, statins, some calcium channel blockers, ciclosporin, certain antiarrhythmics. Ask your pharmacist.

Horse chestnut seed extract

What it is

Aesculus hippocastanum seed. The standardised active is aescin (escin), a mixture of triterpene saponins.

Extracts are standardised to aescin content, usually 16–20%.

The evidence

Horse chestnut has a notable place in the evidence hierarchy of herbal medicine: it is one of the few botanicals with a positive Cochrane review.

A Cochrane systematic review of horse chestnut seed extract for chronic venous insufficiency concluded it is an efficacious and safe short-term treatment for the signs and symptoms, leg pain, oedema, itching and heaviness, based on multiple randomised placebo-controlled trials.

And the stated limits in that review matter: the trials were mostly short-term (typically a few weeks), and longer-term data are lacking.

Some trials also compared it against compression stockings and found broadly comparable symptom relief, which is an interesting finding and is sometimes over-read. Compression has other benefits and is the mainstay; this is an option for people who cannot or will not wear it.

Dose

Trials typically used extract standardised to deliver around 50 mg of aescin twice daily, roughly 100 mg aescin daily, often from around 250–300 mg of standardised extract twice daily.

So the label question is: how much aescin, not how much “horse chestnut”. An unstandardised seed powder tells you nothing.

Safety, and this is important

The extract is well tolerated. The raw plant is not.

Raw horse chestnut seeds, leaves and bark contain esculin, which is toxic, causing gastrointestinal upset and, in significant quantity, more serious effects. Properly manufactured extracts have esculin removed or reduced to safe levels.

This makes manufacturing quality a genuine safety issue here, not just an efficacy one. “Horse chestnut powder” from an unverified source is not the same as a standardised, esculin-controlled extract, and this is a point we would want any buyer to understand.

Other cautions:

Anticoagulants and antiplatelets, aescin has antithrombotic activity; additive risk.

Kidney disease, reported caution, and intravenous aescin has been associated with renal effects.

Liver disease, rare reports of hepatotoxicity.

Pregnancy and lactation, avoid for want of data.

Latex and nut allergy, cross-reactivity reported.

And do not use topically on broken skin.

Side by side

	Diosmin / MPFF	Horse chestnut (aescin)
Source	Citrus flavonoid	Aesculus hippocastanum seed
Evidence grade	Largest trial base; moderate-quality for oedema	Positive Cochrane review, short-term
Best-supported use	Oedema; ulcer healing with compression	Pain, oedema, itching, heaviness
Studied dose	1000 mg MPFF daily	~100 mg aescin daily
Critical formulation point	Must be micronised	Must be standardised and esculin-controlled
Duration of data	Weeks to months	Mostly short-term only
Main interaction	Anticoagulants; CYP3A4 drugs	Anticoagulants; kidney and liver caution
Pregnancy	Avoid	Avoid

The others in the class

Rutin and hydroxyethylrutosides (oxerutins), flavonoids with their own trial base, included in the phlebotonic reviews.

Gotu kola / mandukaparni (Centella asiatica), the classical Ayurvedic ingredient with the most relevant positioning here. Small trials on venous symptoms and capillary permeability, and a long traditional use. Evidence is thinner than the two above. Caution in liver disease, and avoid in pregnancy.

Grape seed extract (OPCs), pine bark extract, butcher’s broom (Ruscus), red vine leaf, each with some trial data, smaller bases.

And the classical Ayurvedic ingredients used in this space, manjistha, sariva, punarnava, guggul, haridra, have traditional use, principally in the context of swelling and inflammation. Preliminary evidence. And guggul’s thyroid effect, drug interactions and contraindication in pregnancy apply here as everywhere.

What this means for a formulation

For anyone specifying a product rather than buying one.

1. Dose at the studied level, or do not borrow the evidence. 1000 mg MPFF, or ~100 mg aescin daily. A formulation at a fifth of that is decorative. This is the honest dividing line in this category.

2. Specify micronised diosmin, and say so on the label. The particle size is part of the active.

3. Specify aescin content, not extract weight alone, and specify esculin limits in the raw material purchase specification. This is a safety control.

4. Do not combine five venoactives at token doses. It looks comprehensive and delivers nothing. Two at proper doses beats six at a tenth each, and this is where most Indian formulations in the category go wrong.

5. Consider the format. 1000 mg of MPFF is bulky, it will be two tablets, or a sachet. A single small capsule cannot contain a studied dose, and pretending otherwise is the commonest misrepresentation here.

6. Print the compression message. A venoactive product’s honest position is alongside compression stockings, and saying so on the pack is both accurate and useful.

7. And print the DVT warning. Sudden unilateral calf pain and swelling needs urgent assessment. A leg-vein product without that line has a gap in it.

Claims, and the regulatory gap this category sits in

This is the part that explains why the same substance is a medicine in one country and a supplement in another.

In parts of Europe, MPFF and standardised horse chestnut extract are licensed medicinal products with approved indications for chronic venous insufficiency. A licensed medicine may state what it treats.

In India, these are typically sold as food supplements under FSSAI’s nutraceutical route, and a food supplement may make no medicinal claims at all.

So the evidence exists, and the licence under which it is sold here does not permit citing it as a treatment claim. That is a genuine regulatory mismatch, and the lawful response is to respect the licence you hold rather than the evidence you wish you could quote.

What is sayable on our labels: vitamin C contributes to normal collagen formation for the normal function of blood vessels, an authorised claim and a relevant one; vitamin C and E contribute to the protection of cells from oxidative stress; and traditional-use statements for manjistha, gotu kola and punarnava.

What is not sayable: treats varicose veins, reduces swelling, relieves leg pain, improves venous tone, repairs valves, or prevents DVT. However good the trial data, these are medicinal claims on a supplement label.

And what we refuse: before-and-after leg photographs; “dissolves” or “clears” varicose veins; and any suggestion that the product substitutes for a Doppler assessment or a procedure.

The honest ranking

If someone with venous symptoms asked us what to do:

1. A properly fitted compression stocking, put on before getting out of bed. Best evidence in the category, cheap, and almost never recommended. (Not if you have peripheral arterial disease, ask first.)

2. Walk, exercise the calf, elevate the legs, manage weight, treat constipation.

3. Get a venous Doppler ultrasound if symptoms affect your life. The definitive treatments are now day-case procedures under local anaesthetic, not the operation people are postponing.

4. And then a venoactive, at a studied dose, alongside compression, for symptom relief.

That is where our product sits: fourth, as an adjunct, at a dose that matches the trials. We would rather sell fewer units honestly positioned than more on a claim the licence does not permit.

When to see a doctor

Urgently:

• Sudden pain, swelling, warmth or redness in one calf, possible DVT
• With sudden breathlessness, chest pain or coughing blood, possible pulmonary embolism, a medical emergency
• Bleeding from a varicose vein, lie down, elevate the leg, apply pressure
• An ulcer or non-healing wound near the ankle
• A hard, red, tender lump along a vein

Soon:

• Symptoms affecting daily life, ask for a venous Doppler
• Skin discolouration or hardening around the ankle, advanced disease
• Before starting either ingredient if you take warfarin, a DOAC, clopidogrel or aspirin
• Before horse chestnut with kidney or liver disease
• Before either in pregnancy or lactation, generally avoided
• If you take statins, calcium channel blockers or ciclosporin, ask about the flavonoid interaction
• Swelling in both legs, the cause may not be venous at all

The short version

1. These two have better evidence than almost anything else in the herbal category, and still do not repair valves.
2. “Venoactive” is a recognised European drug class with no real Indian equivalent.
3. The proposed mechanisms: venous tone, capillary permeability, lymphatic drainage, leukocyte adhesion.
4. MPFF is 90% diosmin with 10% other flavonoids, micronised, that is the studied substance.
5. Micronisation is part of the active. Diosmin is poorly soluble; particle size changes absorption.
6. Reviews support benefit for oedema, moderate quality, with more variable symptom effects.
7. MPFF plus compression improves venous ulcer healing, the most clinically meaningful finding.
8. The studied dose is 1000 mg MPFF daily. A 100 mg product cannot cite the trials.
9. Horse chestnut has a positive Cochrane review for short-term treatment of venous insufficiency.
10. Longer-term horse chestnut data are lacking.
11. Studied dose: around 100 mg aescin daily, from standardised extract.
12. Ask how much aescin, not how much horse chestnut.
13. Raw horse chestnut contains toxic esculin, standardisation is a safety control, not a quality boast.
14. Both interact with anticoagulants. Horse chestnut warrants kidney and liver caution.
15. Citrus flavonoids and CYP3A4, ask about statins, calcium channel blockers, ciclosporin.
16. Avoid both in pregnancy and lactation.
17. Two ingredients at studied doses beat six at a tenth each.
18. A studied dose is bulky, a single small capsule cannot hold it.
19. The evidence is European medicinal; the Indian licence is a food supplement, and the licence governs the label.
20. Compression first, put on before getting out of bed.
21. A venous Doppler decides treatment, and the procedures are now day-case.
22. Print the DVT warning. Sudden one-sided calf swelling is urgent.

Composition detail: Veinova 360 and leg vein gel. Related: पैरों की नसों में दर्द का इलाज, standing all day, what helps your legs, and supplement label compliance in India.